Dr. Reddy's Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
Dr. Reddy's Laboratories has a total shareholder equity of ₹309.3B and total debt of ₹43.8B, which brings its debt-to-equity ratio to 14.2%. Its total assets and total liabilities are ₹466.0B and ₹156.7B respectively. Dr. Reddy's Laboratories's EBIT is ₹67.7B making its interest coverage ratio -227.8. It has cash and short-term investments of ₹63.1B.
Key information
14.2%
Debt to equity ratio
₹43.82b
Debt
| Interest coverage ratio | -227.8x |
| Cash | ₹63.07b |
| Equity | ₹309.28b |
| Total liabilities | ₹156.67b |
| Total assets | ₹465.96b |
Recent financial health updates
No updates
Recent updates
Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy
Aug 13Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements
Nov 29Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook
Oct 27Dr. Reddy's: Growth Supported By New Labels, Profitability
Aug 23Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy
Jun 07Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy
Feb 16Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed
Jan 20Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue
Nov 07Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M
Jul 28Dr. Reddy's launches generic drugs for allergies in US
Jul 22Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases
Jul 05Financial Position Analysis
Short Term Liabilities: RDY's short term assets (₹248.1B) exceed its short term liabilities (₹129.3B).
Long Term Liabilities: RDY's short term assets (₹248.1B) exceed its long term liabilities (₹27.4B).
Debt to Equity History and Analysis
Debt Level: RDY has more cash than its total debt.
Reducing Debt: RDY's debt to equity ratio has reduced from 19.3% to 14.2% over the past 5 years.
Debt Coverage: RDY's debt is well covered by operating cash flow (77.7%).
Interest Coverage: RDY earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 12:35 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dr. Reddy's Laboratories Limited is covered by 81 analysts. 36 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Prashant Nair | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |